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Summary 
During human immunodeficiency virus infection and allergic diseases, characterized by a dominant 
T helper (Th) 2 response, overproduction of prostaglandin E2 (PGE2) is observed. In this paper 
we studied the effect of PGE2 on interleukin (IL)-12 synthesis, because this cytokine has been 
described to be essential in induction of Thl responses. IL-12 synthesis was induced in monocytes 
that were stimulated with Neisseria meningitidis-derived  lipopolysaccharide  in whole blood cultures. 
PGE2 almost completely inhibited lipopolysaccharide induced IL-12 production, whereas IL-6 
production was only partially  inhibited by PGE2.  In contrast,  the production of IL-10 was 
approximately twofold enhanced at these conditions. The effects of PGE2 were due to its cAMP- 
inducing capacity, since they could be mimicked by other cAMP inducers. Recombinant human 
IL-10 also inhibited IL-12 and IL-6 production. However, the inhibitory effect of PGE2 on IL-12 
production was independent of IL-IO since neutralizing anti-IL-10 antibodies were unable to 
reverse this inhibition.  These results suggest  that the capacity of an antigen to induce PGE2 
synthesis may play a crucial role in the development  of either a Thl or Th2 response. 
C 
D4  T cells have been shown to differentiate into Thl 
or Th2 cells, with different cytokine profiles and func- 
tions (1, 2).  Thl cells produce IL-2,  IFN-% and TNF-B, 
activate macrophages, and cause delayed type of hypersensi- 
tivity reactions, whereas Th2 cells produce IL-4 and IL-5, 
cause eosinophilia, and are more specialized in providing B 
cell help for immunoglobulin production. The differentia- 
tion of T cells into either Thl or Th2 cells can be influenced 
by the nature and concentration of the antigen as well as by 
its route of entry, the type of antigen-presenting  cell, and 
soluble factors secreted  by the APC and present in the microen- 
vironment. One of these soluble factors secreted by mono- 
cytes, IL-12, is a major inducer of differentiation  of T cells 
towards the Thl type, while suppressing Th2 cytokine de- 
velopment (3-9). The capacity of IL-12 to stimulate growth 
and IFN-7 production in T  cells and NK cells (4,  10-12) 
is probably  the main reason for its Thl-inducing activity, 
although also IFN-y-independent Thl development has been 
suggested (7-9). Thus far, bacteria, bacterial products,  and 
the protozoan Toxoplasma gondii have been described to in- 
duce production of IL-12 by macrophages and possibly B cells 
(3,  12-14). Less is known about the conditions leading to 
Th2 development. Another product of activated monocytes, 
PGE2, has been suggested to be an important regulatory factor 
in inducing Th2 responses (reviewed in 15). PGE2 and other 
cAMP-increasing agents affect T  helper responses opposite 
to IL-12: the synthesis of Thl cytokines (IL-2 and IFN'y) 
is much more sensitive to inhibition by PGE2/cAMP than 
Th2 cytokine production (IL-4 and IL-5) (16-21). Because 
Thl and Th2 cytokines negatively cross-regulate each other's 
production, the selective  inhibition ofThl cytokines by PGE2 
could result in dominant Th2 responses. In this report we 
describe another mechanism of action of PGE2 on induction 
of Th2 responses, which represents an inhibition by PGE2 
of the production of IL-12 by the APC. Since monocytes are 
able to secrete both PGE2 and IL-12 during antigen presen- 
tation, the balance of these two soluble factors will deter- 
mine whether T cells differentiate  into either Thl or Th2 cells. 
Materials and Methods 
Antibodies and Reagents.  Anti-IL-12  mAb Cll.79 and C8.6 (12) 
were  provided  by Dr. G. Trinchieri  (The Wistar Institute, Philadel- 
phia, PA). The antibodies recognize  both IL-12 p40 and the bioac- 
rive heterodimer  p70, consisting  of  p40 and p35, as described  (12). 
IL-12 p40 and p70 are produced  in parallel  by human PBMC, which 
is the result of p40 mRNA upregulation, whereas p35 mRNA 
expression is only minimally  regulated (12, 13). Anti-ILl0 mAb 
B-T10 and B-N10 were  produced  at Innotherapie  (Besan~on,  France). 
PGE2, 3-isobutyl-l-methylxanthine  (IBMX) and N-2-O-dibutyryl- 
cAMP (DBcAMP) were obtained from Sigma Chemical Co. (St. 
Louis, MO). Recombinant  human (rh) IL-10 was a kind gift from 
Dr. R. de Waal Malefijt  (DNAX, Palo Alto, CA). Neisseria menin- 
gitidis-derived  LPS  was  a gift  from Dr. J.  Poolman (RIVM, 
Bilthoven, The Netherlands). 
Whole Blood Cultures.  Whole blood was obtained  by venipunc- 
ture from normal healthy donors in sodium heparin containing 
sterile blood collecting  tubes (VT-100H tubes; Venoject, Terumo 
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tion of cytokines by endotoxin or endotoxin like substances present 
in culture media, IMDM was ultrafiltrated by means of a hollow 
fiber dialyzer (22) (Hemoflow F5; Fresenius  A.G., Bad Homburg, 
Germany). Whole blood was 1:10 diluted in ultrafiltrated IMDM, 
supplemented with 0.1% FCS, penicillin (100 IU/ml), streptomycin 
(100 #g/ml),  and 50 IU/ml sodiumheparin  (Leo Pharmaceutical  o 
Products B.V., Weesp, The Netherlands). Diluted whole blood was 
cultured in duplicate in 200-/~1 flat-bottomed culture plates (Nunc,  .| 
Roskilde, Denmark). Supernatants were harvested after 18-20 h  -$ 
of culture and cytokine levels were determined. 
Assays for Cytokines 
11.-12 ELISA.  mAb Cll.79 was coated overnight (2/~g/ml in 
0.1 M carbonate buffer, pH 9.6, 100 #l/well) on flat-bottomed mi- 
crotiter plates (Maxisorb; Nunc). All subsequent incubations were 
in 100-/~1 vol at room temperature. The plates were washed twice 
with PBS, 0.02%  (vol/vol) Tween 20 and incubated for 30 min 
with PBS, containing 2% (vol/vol) cow's milk as a blocking step. 
After washing, biotinylated purified mAb C8.6 was added (final 
concentration 0.25 #g/m1) together with Ib12-containing samples 
diluted in high performance ELISA (HPE) buffer (CLB, Amsterdam, 
The Netherlands) for 1.5 h. Thereafter the plates were washed five 
times and incubated with poly-streptavidin-horseradish peroxidase 
(poly-HRP; CLB),  1/10,000 diluted (according to the manufac- 
turer's instruction) in PBS containing 2% (vol/vol) cow's milk for 
0.5  h,  washed,  and developed with a solution of 100 #g/ml of 
3,5,3',5'-tetramethylbenzidine (Merck, Darmstadt, Germany) with 
0.003%  (vol/vol) H202 in 0.11 M  sodium acetate,  pH 5.5  (100 
#l/well). The reaction was stopped by adding an equal volume of 
2 M H2S04 to the wells. Plates were read at 450 nm in a Titertek 
Multiskan reader (Labsystems Multiskan Multisoft, Helsinki, Fin- 
land). Background absorbance at 540 nm was subtracted, rhlL-12 
p70, provided by Dr. S. F. Wolf (Genetics Institute Inc., Cambridge, 
MA) was used as a standard, the detection limit was 4 pg/ml (twice 
the background). 
11,10 ELISA.  The assay was performed identically to the IL-12 
ELISA, except that the blocking step was omitted.  For coating, 
mAb B-N10 was used at 0.5 #g/ml in PBS, and for detection, bi- 
otinylated mAb B-T10 was used at 0.125 #g/ml. rhlL10 was used 
as a standard.  The detection limit was 10 pg/ml. 
11_,6 ELISA.  Procedures were identical to the IL-12 ELISA, with 
the following exceptions: the blocking step was eliminated;  for 
coating, anti-IL-6 mAb CLB.IL6/16 was used at 1 #g/ml in PBS. 
Affinity-purified biotinylated polyclonal sheep anti-IL-6 was used 
for detection at 0.25 #g/ml diluted in PBS, 0.02% (vol/vol) Tween 
20,  0.2%  gelatin (PTG), and  1%  normal sheep serum. Because 
full sensitivity of the II-6 ELISA was not required,  streptavidin- 
HRP (Amersham International, Little Chalfont, United Kingdom) 
diluted 1/1,000 in PTG was used instead of poly-HRP, rhlb6 (23) 
was used as a standard.  The detection limit was 16 pg/ml. 
Results 
In vitro IL-12 production by peripheral blood monocytes 
is induced  by bacterial  products  such  as LPS and Staphylo- 
coccus aureus Cowan I strain (SAC) (12). We used LPS from 
N. meningitidis  to study the regulation of IL-12 production. 
In initial experiments the optimal conditions were established. 
1:10  diluted  peripheral  blood was  stimulated  with  various 
concentrations of LPS (Fig. 1). When instead of whole blood 
cultures PBMC were used, the production of IL-12 was '~ 10- 
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Figure 1.  LPS dose-dependent production oflbl2,11=6, and IF10. 1:10 
diluted whole blood was stimulated with indicated concentrations of LPS. 
After 18-20 h of culture cytokine levels were measured in the superna- 
tants. Results are the mean production of four donors  +  SE. 
fold less on a per cell basis (not shown). Therefore we per- 
formed all experiments with 1:10 diluted whole blood. An 
incubation for 18-20 h turned out to be optimal (data not 
shown). IL-12 was induced by low concentrations of LPS, 
maximal production occurred at 63 pg LPS/ml, and remained 
constant up to 1,000 pg LPS/ml. In further experiments LPS 
was used at a concentration of  250 pg/ml. Concomitant with 
IL-12, other cytokines such as IL-1, IL-8, and TNF-ot were 
produced. Here we concentrated on IL-12, IL-6, and IL-10 
production (Fig.  1). 
IL-12 and PGE2 have opposite effects on induction of Thl 
versus Th2 responses. Therefore we investigated the influence 
of PGE2 on IL-12 production (Fig. 2). PGE2 turned out to 
be a very potent inhibitor of IL-12 production. At concen- 
trations from 10-10 M on, PGE2 dose-dependently inhibited 
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Figure  2.  PGE2  inhibits Ib12 production.  1:10 diluted whole blood 
was stimulated with 250 pg LPS/ml. Graded concentrations of PGE2 were 
used as indicated. After 18 h of culture supernatants were harvested and 
cytokine levels were measured. Results are the mean production  _+ SE 
of five different donors. Mean LPS-induced Ib12 production was: 1,582 
pg/ml; ID6, 5,109 pg/ml; and IIr  286 pg/ml. 
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Figure  3.  cAMP inhibits Ib12 production.  1:10 diluted blood was stimu- 
lated with 250 pg LPS/ml in the absence or presence of DBCAMP or IBMX 
at 50/~M. After 18-20 h of culture cytokines were measured in the super- 
natants.  Results are the mean  +_  SE of four donors. Mean LPS-induced 
IL-12 production was: 1,520 pg/ml; 11,6, 4,412 pg/ml; and IL-10, 261 pg/ml. 
.,  IL-12; ~,  1I.-6; O,  IL-i0. 
the production  of IL-12, yielding  almost complete  inhibi- 
tion at 10 .6 M PGE2 (8% of maximal response).  In con- 
trast, production of IL-6 was much less sensitive to PGE2. 
At 10 -6 M PGE2, the production of IL-6 was inhibited by 
only 40%. Interestingly, the synthesis of IL-10 was approxi- 
mately twofold increased at PGE2 concentrations ranging from 
10 -8  to  10 -6  M. 
Our next goal was to further analyze the mechanism of 
inhibition  of IL-12 (and IL-6) production  by PGE2.  It is 
known that many effects of PGE2 are mediated via an in- 
crease in intracellular cAMP. We therefore analyzed whether 
cAMP could mimic the effects of PGE2. An increase of CAMP 
by DBcAMP indeed strongly inhibited IL-12 production and 
to a lesser extent IL-6 production (Fig. 3). In agreement with 
the findings with PGE2, the synthesis of IL-10 was also en- 
hanced by the addition of DBcAMP. Similar results were ob- 
served when the cAMP phosphodiesterase-inhibitor IBMX 
was  used,  which prevents the breakdown  of intracellular 
cAMP. 
IL-10 has been described as a strong  inhibitor  of IL-12 
production by monocytes  (13). Together with the observa- 
tion that PGE2 enhanced IL-IO production  (Fig.  2),  these 
findings prompted us to investigate the possibility  that the 
inhibitory effects of PGE2 and cAMP were mediated through 
the induction  of IL-10. Exogenous  IL-10 stongly inhibited 
the LPS-induced production  of IL-12 and IL-6 (Fig. 4 A). 
This inhibition was prevented by the simultaneous addition 
of neutralizing anti-IL-10 (Fig. 4 B). In fact, IL-10 antibodies 
even enhanced the LPS-induced cytokine production,  indi- 
cating that endogenously produced IL-10 inhibited the produc- 
tion of IL-12 and IL-6 in the absence of PGE2.  However, 
inhibition  of IL-12 production  by PGE2 (Fig. 4  C) could 
not be reversed by anti-IL-10 (Fig. 4 D). This was not due 
to an incomplete neutralization of endogenous IL-10, because 
exogenous IL-10, at a concentration 10-40 times higher than 
that measured for endogenous IL-10, even more strongly in- 
hibited IL-12 production than PGE2, which inhibition could 
be completely reversed  by anti-IL-10. Therefore  we concluded 
that the inhibitory effect of PGE2 on the production of I1-12 
was largely independent of Ibl0. In contrast, the inhibitory 
effect of PGE2 on LPS-induced production  of IL-6 (Fig. 4 
C) was reversed by anti-IL-10 (Fig. 4 D), indicating that this 
inhibition  was  indirect through  enhancement  of  IL-10 
production. 
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Figure  4.  PGE2 inhibits I1.,12 production 
independent  of IL-10. 1:10 diluted whole blood 
cultures were stimulated with 250 pg LPS/ml. 
PGE2 and 11.-10 were used at indicated con- 
centrations,  anti-Ibl0 mAb BT-10 was used at 
5 #g/m1. After 20 h Ib12 and IL-6 production 
were measured.  Results are the mean  _+ SE of 
four donors.  Mean LPS-induced  Ib12 produc- 
tion was 1,681  pg/ml and mean Ib6 produc- 
tion was 3,032 pg/ml. 
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In this report we show that PGE2 inhibits the production 
of IL-12, in an IL-10-independent  fashion, in whole blood 
cultures stimulated with LPS.  The cells responsible for the 
production of cytokines in whole blood cultures were pre- 
dominantly monocytes, because LPS, used as a stimulant,  is 
a specific stimulus for monocytes, and anti-CD14 inhibited 
LPS-induced cytokine production.  Elimination  of CD14 + 
cells from PBMC revealed that IL-6 and IL-10 were produced 
by monocytes only. After CD14 + depletion, the remaining 
production of IL-12 was 25%, which was also inhibited by 
PGE2.  Depletion of CD19 + cells from PBMC did not re- 
sult in reduction of cytokine production. Therefore we con- 
cluded that  monocytes are the main producers  of IL-12 in 
response to LPS.  However, in whole blood cultures  IL-12 
production was at least 10-fold more efficient than in PBMC 
or adherent cells, whereas for IL-6 and IL-10 production no 
major differences were found in this respect. This was not 
due to the elimination  of granulocytes, because these cells 
did not produce IL-12  (data not  shown). 
After binding to its receptor, PGE2 stimulates adenylate 
cyclase,  which results in elevated cAMP levels  and protein 
kinase A activation (24). The increase of intracellular cAMP 
appeared to be responsible for the effect of PGE2 since other 
cAMP-increasing agents like DBcAMP and IBMX similarly 
inhibited the production of IL-12.  The inhibitory effect of 
PGE2/cAMP on the production of cytokines was specific for 
IL-12, since no such effect was found for IL-8 (not shown) 
and IL-6. These two cytokines were both indirectly inhibited 
through enhancement of IL-10 production. IL-12 is a strong 
inducer of Thl  responses, in vitro as well as in vivo (3,  4, 
6, 7). The fact that PGE2 strongly inhibits the production 
of IL-12 implies  a feedback mechanism  at  the level of the 
APC. Therefore two mechanisms of the PGE2/cAMP pathway 
leading to Th2 responses can be identified: (a) a direct nega- 
tive effect on the production of Thl cytokines such as IL-2 
and IFN-q/(16-21) and (b) downregulation of IL-12 produc- 
tion by monocytes (this report). This latter mechanism might 
be the most important effect of PGE2 on T  helper develop- 
ment, because production of IL-12 is two orders of magni- 
rude more sensitive to inhibition by PGE2 than Thl cytokine 
secretion by T cells (17). Thus, the balance between the secre- 
tion of IL-12 and PGE2 by the antigen-presenting monocyte 
will be crucial in determining whether a Thl or Th2 response 
will dominate. 
There is substantial evidence that  this regulation of Thl 
and Th2 responses indeed occurs at  the level of the APC. 
It has been proposed that HIV infection induces a shift to- 
wards a Th2 response (25), which is believed to be mediated 
by the APC (26).  This is particularly  interesting,  because 
PBMC cells from HIV-infected individuals were shown to 
produce diminished amounts of IL-12, due to a soluble factor 
different from IL-10 (27). Our experiments suggest that this 
factor might be PGE2. This suggestion is supported by the 
fact that HIV infection of monocytes increases  the produc- 
tion of PGE (28, 29). In addition, PBMC from HIV-infected 
individuals have increased levels of cAMP (30). These obser- 
vations together with our results suggest that in HIV-infected 
individuals, the diminished production of IL-12 is due to an 
increase  of PGE2. Moreover, in our hands the reduction of 
IL-12 production by PGE2 was also independent  of IL-IO. 
In atopic dermatitis  and hyper-IgE syndrome patients,  a 
Th2  response is responsible for enhanced  IgE production. 
PBMC isolated from these patients also produced more PGE2 
than normal controls (31, 32). Although a diminished IL-12 
15roduction  by monocytes from  allergic  patients  has  been 
reported yet, based on the above-mentioned results, we spec- 
ulate that the production of IL-12 is indeed reduced in these 
patients. 
The results presented in this report offer new possibilities 
for influencing T helper responses by modulating the secre- 
tion pattern  of the antigen-presenting  cell.  We previously 
reported that the cytokine profile of T memory cells can be 
modulated during the first in vitro stimulation  (33).  These 
findings provide opportunities to treat patients with domi- 
nant Th2 responses by selectively inhibiting the synthesis of 
PGE2 during vaccination or hyposensitization therapy as this 
would increase IL-12 production and cause a shift toward Thl 
cytokine production. 
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